Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
NWSS works with public health departments across the country to track SARS-CoV-2 levels in wastewater so communities can act quickly to prevent the spread of Covid-19.
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
The company enters into collaborations with leading next-generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
Digital PCR format allows for rapid turnaround time to facilitate fast and accurate post-transplant treatment decisions
RNAstorm and DNAstorm RNA/DNA extraction kits will be sold exclusively through the Biotium website and authorized distributors
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)
The increase in PAT is driven by higher sales and lower marketing and depreciation charge vs the same period last year
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
